Table 3 Response in patients receiving G-B in cohort 1 of the GREEN study at final response assessment (intent-to-treat population)

From: Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study

Response, n (%)

All patients (N = 158)

Fit patientsa (n = 70)

Unfit patientsb (n = 88)

Overall response

128 (81.0)

60 (85.7)

68 (77.3)

Complete responsec

55 (34.8)

23 (32.9)

32 (36.4)

Partial response

73 (46.2)

37 (52.9)

36 (40.9)

Stable disease

13 (8.2)

4 (5.7)

9 (10.2)

Progressive disease

2 (1.3)

1 (1.4)

1 (1.1)

Failure (due to missing assessment)

15 (9.5)

5 (7.1)

10 (11.4)

  1. CIRS Cumulative Illness Rating Scale, CrCl creatinine clearance, G-B obinutuzumab plus bendamustine
  2. a CIRS ≤6 and CrCl ≥70 ml/min
  3. b CIRS >6 and/or CrCl <70 ml/min
  4. c Including complete response with incomplete marrow recovery